All News

Letters

Readers discuss the pharmacist's role in OTC selection, voice appreciation for Stan Illich's views, argue that pharmacists need to realize who's in the driver's seat, and share their appreciation for JP.

You leave the day job and what happens? The most fulfilling moments a pharmacist can have occur when you're nowhere near a pharmacy.

New products

A survey of new Rx, new generic, and new OTC products

Women who take HRT for 10 years following menopause have a significantly reduced risk of mortality, heart failure, and heart attack without any increased risk of cancer, DVT, or stroke, a Danish study published on bmj.com showed.

A group of 45 pharmacies in southern Texas are doing their best to get their patients registered, and ready to vote Nov. 6 in the hopes that the state will pay more attention to the struggling pharmacies in the four-county area.

The National Association of Specialty Pharmacy (NASP), a new organization that focuses on specialty pharmacy, had its first event this week at the Academy of Managed Care Pharmacy Educational Conference in Cincinnati, Ohio, and it announced Michael A. Nameth, RPh, MBA, will serve as the interim executive director.

After reviewing new data, FDA has concluded that Budeprion XL 300 mg (bupropion hydrochloride extended-release tablets), manufactured by Impax Laboratories, Inc., and marketed by Teva Pharmaceuticals USA, Inc., is not therapeutically equivalent to GlaxoSmithKline’s Wellbutrin XL 300 mg.

FDA has approved Boston Therapeutic’s petition to file an Abbreviated New Drug Application (ANDA) for a new, chewable tablet formulation of the diabetes drug metformin hydrochloride. The company plans to market the new formulation under the name Pazamet.

The Centers for Disease Control and Prevention (CDC) and the FDA are jointly investigating a meningitis outbreak that has affected approximately 35 people in six states so far. Five patients have died and 30 are ill after receiving an epidural steroid injection contaminated by fungus, according to a report issued from CDC yesterday.

FDA has granted delafloxacin (Rib-X) as a Qualified Infectious Disease Product (QIDP) for the indications of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

While beta-blocker use continues to be the standard of care for patients with coronary artery disease (CAD), especially for those patients who have had a myocardial infarction (MI), these drugs may not be effective long term, according to an online report published Oct. 3 in JAMA.